Barış YILMAZ, Engin ŞENNAROĞLU, Hasan TUNCA, Özlem BALÇIK ŞAHİN, Saadet HASA AKDUR

Metabolik sendromlu kadın hastalar ve P dalga dispersiyonu

Amaç: Atrial fibrilasyon (AF) belirteçlerinden biri olan p dalga dispersiyonunu metabolik sendromlu hastalar ve sağlıklı populasyon arasında karşılaştırmak ve metabolik sendromlu hastalarda artmış p dalga dispersiyonunun AF ve koroner arter hastalığı (KAH) gelişmesinde bir prediktör olabileceğini vurgulamaktır. Yöntem ve Gereçler: Metabolik sendromlu hastalar (n=60) ve sağlıklı bireyler (n=25) yaş, bel çevresi, vücut kitle indeksi, sistolik tansiyon, diyastolik tansiyon, açlık kan şekeri, trigliserid, HDL, LDL, total kolesterol, total kolesterol/ HDL oranı ve EKG kullanarak hesaplanan Pmax (maksimum p dalga süresi), Pmin (minimum p dalga süresi) ve Pd (p dalga dispersiyonu) açısından karşılaştırıldı. Bulgular: Metabolik sendrom (MS) tanılı hastaların ortalama Pmax (106,67±8,37), Pmin (51,33±9,47) ve Pd (55,33±10,32) değerleri ile kontrol grubu Pmax (95,20±7,70), Pmin (59,20±10,37) ve Pd (36,00±11,54) değerleri arasında istatistiki açıdan anlamlı fark bulunmuştur (p40 msn) durumlarında uzun dönemde AF gelişebilecektir. Ancak bu hastaların uzun dönem takibi gerekmektedir.

Female patients with metabolıc syndrome and P wave dispersion

Aim: The aim of this study was to compare the p wave dispersion as one of the markers of atrial fibrillation between patients with metabolic syndrome and healthy population and to emphasize elevated p wave dispersion may be a marker of the atrial fibrillation and coronary artery disease in female patients with metabolic syndrome. Material and Methods: Patients with metabolic syndrome (n=60) and healthy population (n=25) were compared in terms of age, waist circumference, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, triglyceride, HDL, LDL, total cholesterol, total cholesterol/HDL, Pmax (maxımum p wave duratıon), Pmin (minimum p wave duration) and Pd (p wave dispersion). Results: There was a statistically significant difference in terms of Pmax, Pmin and Pd between patients with metabolic syndrome and healthy population (p

PDF

___

1. Türkiye Endokrinoloji ve Metabolizma Derneği Metabolik Sendrom Çalışma Grubunun Metabolik Sendrom Kılavuzu 2007.
2. Buxton AE, Ellison KE, Kirk MM et al. Primary prevention of sudden cardiac death: trials in patients with coronary artery disease. J Interv Card Electrophysiol. 2003; 9:203-6.
3. Loaldi A, Pepi M, Agostoni PG, et al. Cardiac rhythym in hypertension assessed through 24 hour ambulatory electrocardiographic monitoring. Effects of load manipulation with atenolol, verapamil, and nifedipine. Br Heart J. 1983; 50:118-26.
4. Barbier P, Alioto G, Guazi M: Left atrial function and left ventricular filling in hypertensive patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1994; 24:165-170.
5. Cushing EH, Feil HS, Staton EJ, et al. Infarction of the cardiac auricles (atria): clinical pathological and experimental studies. Br Heart J. 1942; 4: 17–34.
6.Wartman WB, Sanders JC. Location of myocardial infarcts with respect to the muscle bundles of the heart. Arch Pathol Lab Med. 1950; 50: 321–64.
7. Hani Sinno et al. Atrial Ischemia Promotes Atrial Fibrillation in Dogs. Circulation 2003; 107:1930-6.
8. Yilmaz R, Demirbag R. P-wave dispersion in patients with stable coronary artery disease and its relationship with severity of the disease. Journal of Electrocardiology 2005; 38:279– 84.
9. Aytemir K, Ozer N, Atalar E. P wave dispersion on 12-lead electrocardiography in patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2000 Jul; 23(7):1109-12.
10. Haffner SM, Valdez RA, Hazuda HP ve ark. Prospective analysis of the insuline-resistance syndrome (syndrome X). Diabetes 1992; 41:715-22.
11. Isomaa B, Almgren P, Tuomi T ve ark. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-9.
12. Trevisan M, Liu J, Bahsas FB ve ark. Syndrome X and mortality: a population based study. Risk factor and life expectancy Research group. Am J Epidemiol 1998; 148:958-66.
13. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med 1995; 98:476.
14. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96:2455.
15. Dilaveris PE ve ark. Simple electrocardiographic markers for the prediction of paroxsymal idiopathic atrial fibrillation. Am Heart J 1998; 135:733–38.
16. Dilaveris PE, Gialofos EJ. Clinical and electrocardiographic predictors of recurrent atrial fibrillation. Pacing Clin Electrophysiol 2000 Mar; 23(3):352-8.
17. Chang M, Lee SH, Lu J. The role of P wave in prediction of atrial fibrillation after coronary artery surgery. İnt J Cardiol 1999 Mar 15; 68(3):303-8.
18. Rosiak M, Bolinska H, Ruta J. P wave dispesion and P wave duration on SAECG in predicting atrial fibrillation with acute myocardial infarction. Ann Noninvasive Electrocardiol 2002 Oct; 7(4):363-8.
19. Elsasser A, Schlepper M, Klovekorn WP, Cai WJ, Zimmermann R, Muller KD, et al. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation 1997; 96:2920.
20. Sugiura T, Iwasaka T, Takahashi N, Yuasa F, Takeuchi M, Hasegawa T, et al. Factors associated with atrial fibrillation in Q wave anterior myocardial infarction. Am Heart J 1991; 121:1409.
21. Hayano J, Sakakibara Y, Yamada M, Ohte N, Fujinami T, Yokoyama K, et al. Decreased magnitude of heart rate spectral components in coronary artery disease. Its relation to angiographic severity. Circulation 1990; 81:1217.
22. Lammers WJ, Kirchhof C, Bonke FI, Allessie MA. Vulnerability of rabbit atrium to reentry by hypoxia. Role of inhomogeneity in conduction and wavelength. Am J Physiol 1992; 262:47.